Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PuraPharm Corp. Ltd. ( (HK:1498) ) has shared an announcement.
PuraPharm Corporation Limited announced the completion of a Patent Licence Agreement and a Subscription Agreement, both involving the issuance of new shares. Under the Patent Licence Agreement, 93,488,372 Consideration Shares were issued, representing a significant portion of the company’s share capital. Additionally, the Subscription Agreement led to the subscription of 46,512,000 new shares, further enlarging the company’s share capital. These transactions are expected to impact the company’s financial structure and market positioning.
The most recent analyst rating on (HK:1498) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on PuraPharm Corp. Ltd. stock, see the HK:1498 Stock Forecast page.
More about PuraPharm Corp. Ltd.
PuraPharm Corporation Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on the development and distribution of herbal medicines and related health products.
Average Trading Volume: 184,991
Technical Sentiment Signal: Sell
Current Market Cap: HK$163.9M
Find detailed analytics on 1498 stock on TipRanks’ Stock Analysis page.